A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects with Ankylosing Spondylitis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2019
At a glance
- Drugs Bimekizumab (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions
- Sponsors UCB
- 09 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Mar 2018 Planned End Date changed from 1 Jul 2023 to 1 Dec 2022.
- 23 Mar 2018 Planned primary completion date changed from 1 Jul 2023 to 1 Dec 2022.